Mechanism of action for leflunomide in rheumatoid arthritis
about
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytesThe Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-AnalysisChronic Renal Transplant Rejection and Possible Anti-Proliferative Drug TargetsOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisLeflunomide: friend or foe for systemic lupus erythematosus?Leflunomide: new antirheumatic drug. Effect on pregnancy outcomesDevelopment of oral immunomodulatory agents in the management of multiple sclerosisDevelopment of a human dihydroorotate dehydrogenase (hDHODH) pharma-similarity index approach with scaffold-hopping strategy for the design of novel potential inhibitorsTherapeutic decisions in multiple sclerosis: moving beyond efficacyThe Open Form Inducer Approach for Structure-Based Drug Design.Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Infection risk in patients on multiple sclerosis therapeutics.High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indicesSjögren's syndrome: current therapies remain inadequate for a common disease.The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis.Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification.Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.The meninges: new therapeutic targets for multiple sclerosis.Purine and pyrimidine pathways as targets in Plasmodium falciparum.Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)Novel targets for the treatment of endometriosis.The effect of leflunomide on cold and vibratory sensation in patients with rheumatoid arthritis.Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing.Mapping the effects of drugs on the immune system.Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy.Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 yearsAn update of teriflunomide for treatment of multiple sclerosis.Hypertension in rheumatoid arthritis.Chronic Diarrhea Associated with High Teriflunomide Blood ConcentrationReview of teriflunomide and its potential in the treatment of multiple sclerosis.Human Cytomegalovirus Can Procure Deoxyribonucleotides for Viral DNA Replication in the Absence of Retinoblastoma Protein Phosphorylation.Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction.Therapeutic options for rheumatoid arthritis.Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?Pharmacotherapy of uveitis.
P2860
Q24800491-B895EEA5-871D-44A3-8D77-84E3372714B1Q26752893-19A7F180-EE3F-4358-A23F-17EEEAF113C5Q26775103-C9834680-879D-4CCB-BEFD-940DB9B6A1E6Q26822611-42CE7E98-34EA-43BC-8F60-DC841454AFB4Q28087414-23E44BF5-A962-4AA3-8898-E35397E4FA87Q28274721-01D296DA-E96F-4FCD-A5C9-C402D006EBC0Q28364465-1BC39980-E738-487F-906C-596DC1B2079FQ28388704-B3E3EAAB-5DDC-4687-83D8-587E5A8855B4Q28539494-2EE8BB3D-F34F-4930-A234-0BC242E22AE4Q28541039-9E66FEDF-5AC0-4854-B2E6-67166D6BB33FQ28554455-6BC62BD0-D50B-40FE-9A12-158CA40DB378Q30354658-51FD38D0-4596-4909-AC8F-C64160F139ECQ30908652-4584EFA7-BFB2-43F0-8F8D-3FE8B64A79C4Q31156888-E53EF8C1-D11E-4AF8-A9E6-3B4306B5DA71Q33927334-13154385-137A-4B54-8FD9-D732FFA94DF4Q34075047-021A3ADB-CEF9-4F46-BBF6-31099FB311EDQ34345424-4AB2F301-9C9C-46C2-972A-B742F66EE1FCQ34389332-8DD062CE-31CC-4E40-AF14-9C6D4D9F2D37Q34465735-8BDF59F7-ED19-467D-AF8C-49C9758DCED8Q34520015-C40B08A7-D958-45F8-8E0F-9FA64589B0F7Q35047952-06841A5D-7233-4123-BEAD-E14004120F9DQ35584727-ECFF23F1-2C3E-4D54-8F40-2624C91612C5Q35870244-899CF8B2-5E44-4EDF-ADB6-BD19BA696873Q35892823-240B25F5-2AEE-4B35-91ED-A222B4AD1B4BQ35911132-FCD68982-0FF1-427A-BC85-E4879076B816Q35981999-CBE45A91-9B2B-49E5-8558-AA84777E5B4BQ36289418-DE5E3BFF-A27A-4AFF-B3C3-6A8C505BEB4BQ36446799-D1254D35-0032-4B7C-9B99-02DB41480D2DQ36515493-F7FBF66F-60EE-4DDB-83E3-BDDF1078E10FQ36613420-693CCC1F-B7DD-4719-A4EE-D1700D17D8F2Q36906008-E06EFFFF-0D62-4769-906F-9CC739EAA6E3Q37158219-00BF932D-7616-465F-A4F8-14E290127A7BQ37208447-361E7B47-4E96-47A2-9273-440F61F030ACQ37235715-361FDC09-EA47-40EC-B081-37FF020AA7CEQ37252945-E2D19682-9392-4550-BA9C-E47B5BC9C06DQ37358239-AF0CF90F-D11F-4745-8D23-D937AA308ACCQ37414694-D7F2E3BF-1ED4-494E-B369-499162719B95Q37552947-969A6BFC-BD80-404D-A871-93172520E8E0Q37637240-5D8AD2FF-EA90-4A8F-B6A1-7A70316F1E52Q37724245-AA580227-60CC-429C-843F-B77DA2FDA3AE
P2860
Mechanism of action for leflunomide in rheumatoid arthritis
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Mechanism of action for leflunomide in rheumatoid arthritis
@ast
Mechanism of action for leflunomide in rheumatoid arthritis
@en
Mechanism of action for leflunomide in rheumatoid arthritis
@nl
type
label
Mechanism of action for leflunomide in rheumatoid arthritis
@ast
Mechanism of action for leflunomide in rheumatoid arthritis
@en
Mechanism of action for leflunomide in rheumatoid arthritis
@nl
prefLabel
Mechanism of action for leflunomide in rheumatoid arthritis
@ast
Mechanism of action for leflunomide in rheumatoid arthritis
@en
Mechanism of action for leflunomide in rheumatoid arthritis
@nl
P2093
P3181
P356
P1433
P1476
Mechanism of action for leflunomide in rheumatoid arthritis
@en
P2093
B J Kirschbaum
C G Frangou
M L Herrmann
R E Morris
P304
P3181
P356
10.1006/CLIM.1999.4777
P407
P577
1999-12-01T00:00:00Z